Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.0
4.9
Journals
IJMS
Special Issues
Biomarkers of Lung Disorders
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Biomarkers of Lung Disorders

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (25 March 2025) | Viewed by 2843

Special Issue Editors

Dr. Alexandru Caraba

E-Mail Website
Guest Editor
3rd Internal Medicine, University of Medicine and Pharmacy "Victor Babeș", Timișoara, Romania
Interests: pulmonary involvement in collagen-vascular diseases (especially interstitial lung disease and pulmonary hypertension)
Special Issues, Collections and Topics in MDPI journals
Dr. Diana Manolescu

E-Mail Website
Guest Editor
Radiology Department, University of Medicine and Pharmacy "Victor Babeș", Timișoara, Romania
Interests: medical imaging in respiratory diseases
Dr. Ovidiu Fira-Mladinescu

E-Mail Website1 Website2
Guest Editor
Pneumology Department, University of Medicine and Pharmacy "Victor Babeș" Timișoara, Romania
Interests: COPD; asthma; interstitial lung fibrosis; pneumonia; pulmonary hypertension
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Biomarkers are represented by any genetic, molecular, histological, biochemical, immunological, or imagistic measurable indicators, which can help early diagnosis, even from the subclinical stages of a disease, can stratifying the evolution risk, and assessing the therapeutic response. They must have high specificity, good discriminative capacity and be easy to determine. Chronic respiratory diseases are an important public health problem, due to their increased prevalence, imposing increased costs for care. That is why their early diagnosis and appropriate treatment is important. Biomarkers can fulfill these requirements. Since chronic respiratory diseases are very diverse, it is necessary to identify specific biomarkers for each type of pathology. Some of these biomarkers are: histidine-rich glycoprotein (HRG), α1-acid glycoprotein (AGP1), α1-antitrypsin (α1AT) and fibronectin (COPD), blood and sputum eosinophils, IgE, vitamin D, serum CD26 and CD14, FeNO (asthma), MUC5B polymorphisms, KL6, SP-A, SP-D, CC16, YKL40,  MMP1, MMP7, LOXL2, CCL18, IL-6, osteopontin (interstitial lung diseases),  NT-proBNP, uric acid, endothelin 1, angiopoietin 2, interleukins (IL-6, IL-8, IL-10) (pulmonary hypertension), epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), proto-oncogene 1 (ROS1), B-Raf proto-oncogene (BRAF), neurotrophic tyrosine receptor kinase (NTRK) and programmed cell death-1 (PD-1) and/or programmed cell death ligand-1 (PD-L1) (lung cancer). These biomarkers, but also others that have not been listed, together with imaging methods (thoracic ultrasonography and high-resolution computed tomography), contribute to the early diagnosis and the appropriate therapeutic strategy in lung pathology.

Dr. Alexandru Caraba
Dr. Diana Manolescu
Dr. Ovidiu Fira-Mladinescu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • thoracic ultrasonography
  • pulmonary high resolution computed tomography
  • COPD
  • asthma
  • pneumonia
  • pulmonary hypertension
  • interstitial lung diseases
  • lung cancer
  • collagen vascular diseases
  • cardiac failure

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

20 pages, 1365 KiB  
Article
Alpha1-Antitrypsin in Lung Diseases: A Cross-Sectional Observational Study
by Csilla Páska, Imre Barta, Zsuzsanna Csoma, Réka Gajdócsi, Viktória Szél, Anna Kerpel-Fronius, Diána Solymosi, Zoltán Örlős and Balázs Antus
Int. J. Mol. Sci. 2025, 26(11), 5400; https://doi.org/10.3390/ijms26115400 - 4 Jun 2025
Viewed by 342
Abstract
Major mutations of SERPINA1, the gene encoding alpha1-antitrypsin (A1AT), are known to cause severe emphysema. Our study aimed to investigate the role of major mutations modulating A1AT levels in several lung pathologies and control groups. Blood samples were collected from healthy non-smokers [...] Read more.
Major mutations of SERPINA1, the gene encoding alpha1-antitrypsin (A1AT), are known to cause severe emphysema. Our study aimed to investigate the role of major mutations modulating A1AT levels in several lung pathologies and control groups. Blood samples were collected from healthy non-smokers (N0 = 85), healthy smokers (N0 = 291), healthy ex-smokers (N0 = 127), smokers with chronic obstructive lung disease (COPD, N0 = 187), ex-smokers with COPD (N0 = 64), and patients with asthma (N0 = 194), interstitial lung disease (ILD) (N0 = 93), sarcoidosis (N0 = 30) and cystic fibrosis (N0 = 26). Clinical and respiratory parameters, A1AT levels, the extent of emphysema and comorbidities on low-dose CT scans were evaluated, and patients answered a smoking history and comorbidity questionnaire. A1AT single-nucleotide polymorphisms were determined for the S, Z, M2/M4, 0 and eQTL locations by SNP probes using real-time PCR. A1AT levels showed significant differences between cigarette smoke-induced and other lung diseases. Compared to controls, A1AT levels were found to be lower in sarcoidosis and increasingly higher in smokers and patients with COPD, ILD and CF, respectively. The presence and pattern of emphysema were found to influence A1AT levels: lower values were observed in COPD patients without emphysema, while higher values were observed in patients with central and panlobular emphysema. Antitrypsin levels increased with COPD GOLD stages and asthma GINA stages. Variable A1AT levels were also found in ILD subgroups. The distribution of variants at the S, Z, M2/M4 and 0 polymorphic sites and the eQTL location showed no significant differences between patient groups with impaired lung function, except for Z heterozygotes, which were prevalent in patients with severe asthma. The eQTL TT genotypes had higher A1AT levels and the occurrence of emphysema and/or bronchitis was increased. A1AT levels correlated with several clinical and respiratory parameters in pulmonary patients, while FEV1/FVC inversely correlated with levels of A1AT. Molar antielastase activity was increased in smokers and patients with lung diseases; however, in COPD, antielastase activity decreased. The most reduced antielastase activity could be found in CF. Certain genotypes were characterized by increased cardiovascular comorbidity scores and antitrypsin levels. Our data suggest that in addition to emphysema, A1AT may play an important role in the development of a wide variety of lung diseases and cardiovascular comorbidities. Further research is needed to clarify the role of A1AT and its regulation in lung pathologies. Full article
(This article belongs to the Special Issue Biomarkers of Lung Disorders)
►▼ Show Figures

Figure 1

16 pages, 2497 KiB  
Article
Expression Levels of MUC5AC and MUC5B in Airway Goblet Cells Are Associated with Traits of COPD and Progression of Chronic Airflow Limitation
by Terezia Pincikova, Heta Merikallio, Ioanna Kotortsi, Reza Karimi, Chuan-Xing Li, Elisa Lappi-Blanco, Sara K. Lindén, Médea Padra, Åsa M. Wheelock, Sven Nyrén, Carl Magnus Sköld and Riitta L. Kaarteenaho
Int. J. Mol. Sci. 2024, 25(24), 13653; https://doi.org/10.3390/ijms252413653 - 20 Dec 2024
Viewed by 2048
Abstract
Mucins 5AC (MUC5AC) and 5B (MUC5B) are the major mucins providing the organizing framework for the airway’s mucus gel. We retrieved bronchial mucosal biopsies and bronchial wash (BW) samples through bronchoscopy from patients with chronic obstructive pulmonary disease (n = 38), healthy [...] Read more.
Mucins 5AC (MUC5AC) and 5B (MUC5B) are the major mucins providing the organizing framework for the airway’s mucus gel. We retrieved bronchial mucosal biopsies and bronchial wash (BW) samples through bronchoscopy from patients with chronic obstructive pulmonary disease (n = 38), healthy never-smokers (n = 40), and smokers with normal lung function (n = 40). The expression of MUC5AC and MUC5B was assessed immunohistochemically. The mucin concentrations in BW were determined using the slot-blot technique. The immunohistochemical expression of MUC5AC and MUC5B was localized to goblet cells and submucosal glands. Smokers had higher MUC5AC and lower MUC5B goblet cell expression and higher concentrations of soluble MUC5AC in BW than never-smokers. The MUC5B expression in goblet cells correlated positively with expiratory air flows, diffusing capacity, and the dyspnoea score. Chronic bronchitis, emphysema, and the progression of chronic airflow limitation during a median follow-up time of 8.4 years were associated with higher MUC5AC and lower MUC5B expression in goblet cells. Sustainers, slow progressors, and rapid progressors of airflow obstruction differed in their MUC5B expression at baseline. Emphysema and bronchial wall thickening on CT at a follow-up visit were associated with lower MUC5B expression at baseline. Our findings strengthen the hypothesis that MUC5AC and MUC5B are yet another contributing factor to smoking-associated lung disease progression. Full article
(This article belongs to the Special Issue Biomarkers of Lung Disorders)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop